Signalling and Acquired Resistance to Targeted Cancer Therapeutics

Meeting Background
Tumour cells rapidly evolve to acquire resistance to new, targeted therapeutics such as protein kinase inhibitors. Understanding such ‘acquired resistance’ has obvious clinical relevance but also reveals the plasticity of signalling pathways and their ability to remodel through feedback and cross-talk. This meeting will highlight advances in understanding how tumour cells adapt to inhibition of specific signalling pathways and the role this plays in acquired resistance.

RAF-MEK-ERK signalling
Tyrosine kinases and their inhibitors
TOR/PI3K inhibitors
Kinome reprogramming
Cell survival/cell death signalling
Systems and computational biology approaches
+ show speakers and program
Claudia Wellbrock (University of Manchester, United Kingdom)
Forest White (Massachusetts Institute of Technology, U.S.A.)
Gary Johnson (University of North Carolina, U.S.A)
Georgia Hatzivassiliou (Genentech, San Francisco, U.S.A)
Jane Apperley (Imperial College London, United Kingdom)
Julian Downward (CRUK London Research Institute, United Kingdom)
Julio Saez-Rodriguez (University of Cambridge, United Kingdom)
Maria Soengas (Spanish National Cancer Research Centre, Spain)
Martin Michaelis (University of Kent, United Kingdom)
Mohamed Bentires-Alj (Friedrich Miescher Institute for Biomedical Research, Switzerland)
Nils Blüthgen (Charite - Universitätsmedizin Berlin, Germany)
Violeta Serra (Vall D’Hebbron Institute of Oncology, Spain)

5 Jan - 7 Jan 2014
United Kingdom
meeting website